ERAS Earnings — Erasca, Inc. Common Stock Post-ER Performance | BigEarnings
ERAS — Erasca, Inc. Common Stock
XNAS
Price$19.17
Market Cap$6.7B
P/E—
52W Range$1.33 – $24.28
Next Earnings2026-08-11
About Erasca, Inc. Common Stock
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
